Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

Alvontech (ALVO)

Alvontech
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:ALVO
DateTimeSourceHeadlineSymbolCompany
21/05/202422:15GlobeNewswire Inc.Alvotech Reports Financial Results for First Quarter of 2024 and Provides a Business UpdateNASDAQ:ALVOAlvontech
21/05/202415:05Business WireAlvotech and Dr. Reddy’s Enter Into Collaboration for Commercialization of AVT03 (denosumab), a Biosimilar Candidate to Prolia® & Xgeva® in the U.S., Europe and UKNASDAQ:ALVOAlvontech
21/05/202413:00GlobeNewswire Inc.Alvotech and Dr. Reddy’s enter into collaboration for commercialization of AVT03 (denosumab), a biosimilar candidate to Prolia® & Xgeva® in the U.S., Europe and UKNASDAQ:ALVOAlvontech
21/05/202412:13IH Market NewsU.S. Index Futures Open Lower Amid Nasdaq Record, Fed SpeechesNASDAQ:ALVOAlvontech
21/05/202401:25Business WireTeva and Alvotech Announce SIMLANDI® (adalimumab-ryvk) Injection Now Available in the U.S.NASDAQ:ALVOAlvontech
21/05/202401:25GlobeNewswire Inc.Teva and Alvotech Announce SIMLANDI® (adalimumab-ryvk) Injection Now Available in the U.S.NASDAQ:ALVOAlvontech
13/05/202413:00GlobeNewswire Inc.Alvotech Announces Webcast of First Quarter 2024 Financial Results on May 22, 2024, at 8:00 am EDT (12 noon GMT)NASDAQ:ALVOAlvontech
02/05/202412:15GlobeNewswire Inc.Alvotech Announces Participation at BofA Securities Healthcare Conference 2024NASDAQ:ALVOAlvontech
30/04/202409:00GlobeNewswire Inc.U.S. Commercialization Agreement with Quallent to Drive Patient Savings with First High-Concentration Citrate-Free Interchangeable Biosimilar to Humira® (adalimumab)NASDAQ:ALVOAlvontech
30/04/202409:00Business WireU.S. Commercialization Agreement with Quallent to Drive Patient Savings with First High-Concentration Citrate-Free Interchangeable Biosimilar to Humira® (adalimumab)NASDAQ:ALVOAlvontech
24/04/202409:00GlobeNewswire Inc.Alvotech Announces Topline Results from a Confirmatory Clinical Study for AVT05, a Proposed Biosimilar for Simponi® (golimumab)NASDAQ:ALVOAlvontech
19/04/202411:10GlobeNewswire Inc.Alvotech signs U.S. agreement to expand access for newly approved high-concentration interchangeable biosimilar to Humira® (adalimumab)NASDAQ:ALVOAlvontech
16/04/202422:43Business WireAlvotech and Teva Announce U.S. FDA Approval of SELARSDI™ (ustekinumab-aekn), biosimilar to Stelara® (ustekinumab)NASDAQ:ALVOAlvontech
16/04/202422:30GlobeNewswire Inc.Alvotech and Teva Announce U.S. FDA Approval of SELARSDI™ (ustekinumab-aekn), biosimilar to Stelara® (ustekinumab)NASDAQ:ALVOAlvontech
03/04/202412:41GlobeNewswire Inc.Alvotech Hosts Audio Call for Investors at 8:15 am EDT on April 3, 2024NASDAQ:ALVOAlvontech
22/03/202420:15GlobeNewswire Inc.Alvotech Announces Increase in Number of Own SharesNASDAQ:ALVOAlvontech
20/03/202420:15GlobeNewswire Inc.Alvotech Reports Financial Results for Full Year 2023 and Provides a Business UpdateNASDAQ:ALVOAlvontech
20/03/202411:17IH Market NewsU.S. Index Futures Trade Sideways Amid Anticipation of Fed’s Policy Update; Oil Prices DipNASDAQ:ALVOAlvontech
05/03/202421:00GlobeNewswire Inc.Alvotech Announces Webcast of Full Year 2023 Financial Results on March 21, 2024, at 8:00 am ETNASDAQ:ALVOAlvontech
29/02/202421:05GlobeNewswire Inc.Alvotech Appoints Interim Chief Quality OfficerNASDAQ:ALVOAlvontech
26/02/202409:25GlobeNewswire Inc.Alvotech Accepts Offer for the Sale of Shares for a value of approximately USD 166 million at a Purchase price of USD 16.41 (ISK 2,250) per ShareNASDAQ:ALVOAlvontech
24/02/202401:15GlobeNewswire Inc.Alvotech and Teva Announce U.S. Approval of SIMLANDI® (adalimumab-ryvk) injection, the first interchangeable high-concentration, citrate-free biosimilar to Humira®NASDAQ:ALVOAlvontech
24/02/202401:15Business WireAlvotech and Teva Announce U.S. Approval of SIMLANDI® (adalimumab-ryvk) injection, the first interchangeable high-concentration, citrate-free biosimilar to Humira®NASDAQ:ALVOAlvontech
15/02/202411:30GlobeNewswire Inc.Alvotech Announces Expected Global Market Entry Dates for AVT04 Biosimilar to Stelara® (ustekinumab)NASDAQ:ALVOAlvontech
29/01/202409:00GlobeNewswire Inc.Alvotech Announces Positive Top-Line Results from a Pharmacokinetic Study for AVT03, a Proposed Biosimilar for Prolia® and Xgeva®NASDAQ:ALVOAlvontech
19/01/202417:31Dow Jones NewsAlvotech Shares Climb After FDA Concludes Facility InspectionNASDAQ:ALVOAlvontech
19/01/202416:30GlobeNewswire Inc.Alvotech Provides Update on Status of Biologics License Applications for AVT02 and AVT04NASDAQ:ALVOAlvontech
10/01/202408:30GlobeNewswire Inc.STADA and Alvotech secure approval for Uzpruvo, Europe’s first ustekinumab biosimilar to StelaraNASDAQ:ALVOAlvontech
03/01/202408:30GlobeNewswire Inc.Alvotech Clinical Study Results Demonstrate Therapeutic Equivalence between Biosimilar Candidate AVT06 and Reference Product Eylea® (aflibercept)NASDAQ:ALVOAlvontech
29/11/202309:00GlobeNewswire Inc.Alvotech Announces Positive Top-Line Results from a Pharmacokinetic Study for AVT05, a Proposed Biosimilar for Simponi® and Simponi Aria®NASDAQ:ALVOAlvontech
 Showing the most relevant articles for your search:NASDAQ:ALVO